
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co. is anticipated to experience robust growth beginning in the second half of 2025 and extending into 2026 and 2027, driven by a diverse portfolio that includes successful vaccines and innovative treatments in oncology and infectious diseases. The company is strategically positioned to capture significant market share with its Capvaxive pneumococcal vaccine and RSV antibody products, while its transition to Keytruda’s subcutaneous formulation may further bolster revenues post-loss of exclusivity. Additionally, anticipated launches of clesrovimab and advancements in ongoing trials, such as MK-8527 for HIV prevention, underscore Merck's ongoing commitment to expanding its market presence and product offerings.
Bears say
Merck & Co faces significant challenges impacting its stock outlook, primarily due to anticipated revenue declines from its Keytruda immunotherapy treatment following the loss of exclusivity and increased competition from biosimilars, with projections estimating a revenue reduction of up to 58%. Additionally, performance issues with other products, such as Winrevair, which underperformed relative to both management expectations and consensus estimates, raise concerns about the company's ability to maintain growth across its portfolio. Overall, these factors contribute to a lowered valuation and heightened uncertainty regarding Merck's future revenue streams, particularly in light of regulatory pressures from initiatives like the Medicare IRA price negotiations.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares